Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) closed at $7.66 up 0.26% from its previous closing price of $7.64. In other words, the price has increased by $0.26 from its previous closing price. On the day, 2.73 million shares were traded. BCRX stock price reached its highest trading level at $7.69 during the session, while it also had its lowest trading level at $7.5101.
Ratios:
For a deeper understanding of Biocryst Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.56 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 33.85. For the most recent quarter (mrq), Quick Ratio is recorded 1.84 and its Current Ratio is at 1.87.
On October 01, 2025, Evercore ISI Downgraded its rating to In-line which previously was Outperform but kept the price unchanged to $8.
On April 29, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $20.Cantor Fitzgerald initiated its Overweight rating on April 29, 2025, with a $20 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 01 ’25 when Barnes Alane P sold 91,004 shares for $7.10 per share. The transaction valued at 646,511 led to the insider holds 416,152 shares of the business.
Barnes Alane P sold 50,906 shares of BCRX for $367,216 on Dec 02 ’25. The Chief Legal Officer now owns 365,246 shares after completing the transaction at $7.21 per share. On Dec 03 ’25, another insider, Barnes Alane P, who serves as the Chief Legal Officer of the company, sold 19,770 shares for $7.65 each. As a result, the insider received 151,240 and left with 345,476 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 1612761088 and an Enterprise Value of 2082997120. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.69. Its current Enterprise Value per Revenue stands at 3.473 whereas that against EBITDA is 25.898.
Stock Price History:
The Beta on a monthly basis for BCRX is 0.80, which has changed by 0.0052632093 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, BCRX has reached a high of $11.31, while it has fallen to a 52-week low of $6.00. The 50-Day Moving Average of the stock is 7.29%, while the 200-Day Moving Average is calculated to be -7.54%.
Shares Statistics:
For the past three months, BCRX has traded an average of 4.93M shares per day and 4179710 over the past ten days. A total of 210.52M shares are outstanding, with a floating share count of 194.85M. Insiders hold about 7.45% of the company’s shares, while institutions hold 95.21% stake in the company. Shares short for BCRX as of 1764288000 were 37382162 with a Short Ratio of 7.59, compared to 1761868800 on 32471309. Therefore, it implies a Short% of Shares Outstanding of 37382162 and a Short% of Float of 17.819999.
Earnings Estimates
The dynamic stock of Biocryst Pharmaceuticals Inc (BCRX) is currently attracting attention from 4.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.12, with high estimates of $0.13 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.47 and $0.09 for the fiscal current year, implying an average EPS of $0.34. EPS for the following year is $0.29, with 4.0 analysts recommending between $0.7 and -$0.04.
Revenue Estimates
A total of 9 analysts believe the company’s revenue will be $151.33M this quarter.It ranges from a high estimate of $156.03M to a low estimate of $145.14M. As of. The current estimate, Biocryst Pharmaceuticals Inc’s year-ago sales were $131.53MFor the next quarter, 9 analysts are estimating revenue of $156.33M. There is a high estimate of $160.58M for the next quarter, whereas the lowest estimate is $151M.
A total of 9 analysts have provided revenue estimates for BCRX’s current fiscal year. The highest revenue estimate was $624.31M, while the lowest revenue estimate was $613.1M, resulting in an average revenue estimate of $619.56M. In the same quarter a year ago, actual revenue was $450.71MBased on 10 analysts’ estimates, the company’s revenue will be $665.48M in the next fiscal year. The high estimate is $691.44M and the low estimate is $608M.
